Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Dextran Sulfate Sodium-induced Colitis
100%
Brugia Malayi
100%
Cystatin
100%
Disease Severity
50%
Splenocytes
50%
Dextran Sulfate Sodium
50%
Myeloperoxidase Activity
50%
Disease Activity Score
50%
Colonic mucosa
50%
Dose-dependent
50%
Colitis Mice
50%
Therapeutic Effect
25%
Weight Loss
25%
Interleukin-6
25%
Balb C Mice
25%
Inflammatory Bowel Disease
25%
Colon
25%
Therapeutic Agents
25%
MRNA Expression
25%
Ulcerative Colitis
25%
Therapeutic Implications
25%
Interleukin-10
25%
Interleukin-17 (IL-17)
25%
Helminths
25%
Colitis
25%
Anti-inflammatory Activity
25%
Immunomodulation
25%
Cytokine Profile
25%
Interleukin-5 (IL-5)
25%
Peritoneal Exudate Cells
25%
In Vitro Anti-inflammatory Activity
25%
Macroscopic Examination
25%
Colon Injury
25%
Mucosal Edema
25%
Anti-inflammatory Potential
25%
Recombinant Cystatin
25%
Promising Therapeutics
25%
Histopathological Score
25%
Pharmacology, Toxicology and Pharmaceutical Science
Dextran Sulfate Sodium-Induced Colitis
100%
Cystatin
100%
Brugia malayi
100%
Anti-Inflammatory Drug
75%
Colitis
75%
Dextran Sulfate
50%
Disease Activity
50%
Disease Severity
50%
Myeloperoxidase
50%
Inflammatory Bowel Disease
25%
Cytokine
25%
Therapeutic Effect
25%
Tumor Necrosis Factor
25%
Bagg Albino Mouse
25%
Interleukin 6
25%
Interleukin 10
25%
Edema
25%
Helminth
25%
Ulcerative Colitis
25%
Immunomodulation
25%
Interleukin 17
25%
Peritoneum Exudate
25%
Colon Injury
25%
Interleukin 5
25%
Messenger RNA
25%